Table 1. Characteristics of 1,316 older patients with non-metastatic rectal cancer receiving preoperative treatment and surgical resection by postoperative treatment type, 2004-2009.

Characteristics	No postoperative chemotherapy		Postoperative 5-FU/ capecitabine alone		Postoperative oxaliplatin
	n=666	%	n=309	%	n=341	%
Age at diagnosis
66-69 years	129	19	85	28	141	41
70-74 years	213	32	98	32	113	33
75-79 years	177	27	73	24	74	22
80+ years	147	22	53	17	13	4
Male	381	57	178	58	214	63
Race/ethnicity
White, Non-Hispanic	526	79	244	79	287	84
Black, Non-Hispanic	43	6	16	5	14	4
Other, Non-Hispanic	46	7	23	7	23	7
Hispanic	51	8	26	8	17	5
Marital status
Married	385	58	196	63	220	65
Widowed	173	26	62	20	61	18
Single	58	9	23	7	30	9
Separated or Divorced	50	8	28	9	30	9
Metropolitan residence	598	90	257	83	309	91
% living below poverty line (census tract)
Quartile 1 (low)	151	23	65	21	107	31
Quartile 2	168	25	71	23	90	26
Quartile 3	173	26	82	27	76	22
Quartile 4 (high)	174	26	91	29	68	20
AJCC pathologic stage
0 and I	204	31	75	24	54	16
II	298	45	121	39	120	35
III	164	25	113	37	167	49
Diagnosis year
2004	112	17	62	20	26	8
2005	125	19	61	20	62	18
2006	110	17	46	15	60	18
2007	118	18	46	15	64	19
2008	91	14	43	14	77	23
2009	110	17	51	17	52	15
Rectum vs. Rectosigmoid	597	90	278	90	309	91
Preoperative chemoradiation vs. radiation therapy only	527	79	290	94	312	91
Selected comorbidities
Congestive heart failure	43	6	14	5	NR	NR
COPD	65	10	23	7	26	8
Diabetes without sequelae	141	21	72	23	60	18
Diabetes with sequelae	19	3	11	4	13	4
30-day post-operative hospitalization	245	37	69	22	58	17
Predicted probability of ADL-D (median, IQR)	0.034 (0.023, 0.054)		0.031 (0.021, 0.046)		0.026 (0.020, 0.038)

Abbreviations: 5-FU=5-fluorouracil; NR=not reportable due to cell size less than 11, AJCC=American Joint Commission on Cancer, COPD=chronic obstructive pulmonary disease, ADL-D=activities of daily living dependence.